The Christie charity
The table below shows a list of The Lymphoma Group's current clinical trials open/due to open for recruitment for Diffuse large B-cell lymphoma patients.
If you would like to know how to access our trials please click here
|
Trial Name |
Description |
Click the link for more information (external page) |
|
GEN3013 |
Phase 1/2 study using antibody GEN3013 to target CD20- expressing cells in patients with B cell non Hodgkin lymphoma
|
|
|
JCAR017 |
Phase 2 study determining efficacy and safety of JCAR017 Suitable for patients with lymphoma which has come back after previous treatment
|
|
|
GO29781 |
A phase 1/1b trial testing mosunetuzumab, on its own or with atezolizumab
|
|
|
GCT3013-02 |
A phase 1b/2 trial of a targeted treatment, epcoritamab, in combination with different chemotherapy regimens, in people with B-cell non-Hodgkin lymphoma.
|
|
|
LOTIS-3 |
A phase 1/2 trial of loncastuximab tesirine and ibrutinib in people with relapsed or refractory diffuse large B-cell lymphoma or mantle cell lymphoma.
|
|
|
LOTIS-5 |
A phase 3 trial of loncastuximab tesirine and rituximab Vs standard immunochemotherapy in people with relapsed of refractory diffuse large B-cell lymphoma.
|
Sign up link will be added soon |
|
GCT3013-05 |
A phase 3 trial of epcoritamab Vs standard chemotherapy in people with relapsed or refractory diffuse large B-cell lymphoma.
|
Sign up link will be added soon |
|
|
A phase 3 trial of tafasitamab plus lenalidomide in addition to R-CHOP Vs R-CHOP in people with untreated high-risk diffuse large B-cell lymphoma.
|
Sign up link will be added soon |
|
REMoDL-A |
A phase 2 trial
|
Sign up link will be added soon |
With special thanks to the following:
